2-[tert-butoxycarbonyl-[(1S)-1-phenylethyl]amino]acetic acid | 180344-10-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[tert-butoxycarbonyl-[(1S)-1-phenylethyl]amino]acetic acid
• 英文别名: 2-[(2-methylpropan-2-yl)oxycarbonyl-[(1S)-1-phenylethyl]amino]acetic acid
• CAS: 180344-10-9
• 化学式: C₁₅H₂₁NO₄
• 分子量: 279.336
• InChiKey: XWRXGJGROYGXTF-NSHDSACASA-N

物化性质

• 沸点：
  410.9±34.0 °C(Predicted)
• 密度：
  1.145±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[tert-butoxycarbonyl-[(1S)-1-phenylethyl]amino]acetic acid 在 盐酸 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 29.0h， 生成 [4-((R)-3-((S)-4-Isopropyl-2-oxo-oxazolidin-3-yl)-2-{[{[methyl-(2-pyridin-2-yl-ethyl)-carbamoyl]-methyl}-((S)-1-phenyl-ethyl)-carbamoyl]-methyl}-3-oxo-propyl)-thiazol-2-yl]-carbamic acid 2,2,2-trichloro-ethyl ester
  参考文献：
  名称：

  Discovery of non-peptidic P 2 –P 3 butanediamide renin inhibitors with high oral efficacy

  摘要：

  A new series of non-peptidic renin inhibitors having a 2-substituted butanediamide moiety at the P-2 and P-3 positions has been identified. The optimized inhibitors have IC50 values of 0.8 to 1.4 nM and 2.5 to 7.6 nM in plasma renin assays at pH 6.0 and 7.4, respectively. When evaluated in the normotensive cynomolgus monkey model, two of the most potent inhibitors were orally active at a dose as low as 3 mg/kg. These potent renin inhibitors are characterized by oral bioavailabilities of 40 and 89% in the cynomolgus monkey. Inhibitor 3z (BILA 2157 BS) was selected as candidate for pre-development. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(98)00265-x
• 作为产物：
  描述：

  methyl 2-[tert-butoxycarbonyl-[(1S)-1-phenylethyl]amino]acetate 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 以88%的产率得到2-[tert-butoxycarbonyl-[(1S)-1-phenylethyl]amino]acetic acid
  参考文献：
  名称：

  [EN] INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE
  [FR] INHIBITEURS D'INDOLÉAMINE 2,3-DIOXYGÉNASE

  摘要：

  该发明涉及式(I)的化合物，或其药学上可接受的对映体或盐。本发明还涉及将式(I)的化合物用作色氨酸2,3-二氧化酶的选择性抑制剂。该发明还涉及将式(I)的化合物用于治疗或预防癌症、感染、中枢神经系统疾病或紊乱以及免疫相关疾病，无论是作为单一药剂还是与其他疗法结合使用。

  公开号：

  WO2017153459A1

文献信息

• [EN] 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE<br/>[FR] COMPOSÉS DE 3-HYDROXY-IMIDAZOLIDIN-4-ONE UTILISÉS EN TANT QU'INHIBITEURS DE L'INDOLÉAMINE 2,3-DIOXYGÉNASE
  申请人：NETHERLANDS TRANSLATIONAL RES CENTER B V

  公开号：WO2019043103A1

  公开（公告）日：2019-03-07

  The invention relates to a compound of Formula (I) : Formula (I), or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies.

  该发明涉及一种公式(I)的化合物：公式(I)，或其药学上可接受的对映体或盐。本发明还涉及将公式(I)的化合物用作色氨酸2,3-双加氧酶的选择性抑制剂。该发明还涉及使用公式(I)的化合物治疗或预防癌症、感染、中枢神经系统疾病或障碍以及免疫相关疾病，无论是作为单一药物还是与其他治疗方法联合使用。
• 3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase
  申请人：Netherlands Translational Research Center B.V.

  公开号：US11053230B2

  公开（公告）日：2021-07-06

  The invention relates to a compound of Formula (I): Formula (I), or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies.

  本发明涉及一种式（I）化合物：式（I）或药学上可接受的对映体或其盐。本发明还涉及式（I）化合物作为吲哚胺 2，3-二氧化酶选择性抑制剂的用途。本发明还涉及式（I）化合物用于治疗或预防癌症、感染、中枢神经系统疾病或紊乱以及免疫相关紊乱等疾病的用途，可作为单一药物或与其他疗法联合使用。
• INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE
  申请人：Netherlands Translational Research Center B.V.

  公开号：EP3426638B1

  公开（公告）日：2020-05-06
• 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE
  申请人：Netherlands Translational Research Center B.V.

  公开号：EP3676263B1

  公开（公告）日：2021-10-06
• [EN] INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE<br/>[FR] INHIBITEURS D'INDOLÉAMINE 2,3-DIOXYGÉNASE
  申请人：NETHERLANDS TRANSLATIONAL RES CENTER B V

  公开号：WO2017153459A1

  公开（公告）日：2017-09-14

  The invention relates to a compound of Formula (I), or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies.

  该发明涉及式(I)的化合物，或其药学上可接受的对映体或盐。本发明还涉及将式(I)的化合物用作色氨酸2,3-二氧化酶的选择性抑制剂。该发明还涉及将式(I)的化合物用于治疗或预防癌症、感染、中枢神经系统疾病或紊乱以及免疫相关疾病，无论是作为单一药剂还是与其他疗法结合使用。